Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Gastrointestinal bleeding tied to poorer outcomes in STEMI patients

18 Jul 2019

While gastrointestinal bleeding (GIB) is uncommon among patients with ST-elevation myocardial infarction (STEMI), the complication leads to greater morbidity, mortality and resource utilization, reports a new study.

The study included 1,450,696 STEMI patients, of which only 2.2 percent (n=32,624) were complicated with GIB. The incidence rate of GIB in STEMI decreased over time, going from 2.7 percent in the year 2003 to 2.0 percent in 2016 (p-trend<0.001). Those with GIB were older (73±14 vs 68±15 years; p<0.001) and were more likely to be female (44.9 percent vs 36.8 percent; p<0.001).

Compared with patients who did not develop the complication, those with GIB had significantly higher incidence rates of in-hospital mortality (28.2 percent vs 11.1 percent; p<0.001), acute kidney injury (29.8 percent vs 11.0 percent; p<0.001) and stroke (3.5 percent vs 1.5 percent; p<0.001).

In addition, patients with GIB were also more likely to need blood transfusion (29.3 percent vs 5.8 percent; p<0.001) and new dialysis requirements (2.5 percent vs 0.7 percent; p<0.001), and were less likely to be discharged from the hospital (nondischarge: 41.5 percent vs 25.8 percent; p<0.001).

Median length of stay (6 vs 3 days; p<0.001) as well as mean cost (USD 30,752±42,802 vs 21,372±23,552; p<0.001) were similarly significantly higher in patients who developed GIB.

“To our knowledge, this is the largest nationwide analysis examining the incidence and outcomes of GIB in patients admitted with STEMI,” said researchers. “[W]e believe that this study offers important insights into a high-risk cohort of patients in whom data to guide optimal therapy are scarce.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.